Literature DB >> 6941466

HLA-D antigen frequencies in Sjögren's syndrome. Differences between the primary and secondary form.

R Manthorpe, N Morling, P Platz, L P Ryder, A Svejgaard, M Thomsen.   

Abstract

HLA-A, B, C and D typing was performed in 19 patients with primary Sjögren's syndrome (primary SS) and in 15 patients with rheumatoid arthritis (RA) and secondary Sjögren's syndrome (RA-SS). In the primary SS group, the frequency of HLA-Dw2 was increased (p less than 0.01; "corrected" p greater than 0.05) while the frequency of Dw3 was non-significantly increased. In the RA-SS patients, the frequency of HLA-Dw4 was increased to 84.6% (relative risk = 22.8; p less than 0.001) and the frequency of Dw2 was non-significantly decreased. An increased frequency of Dw2 in primary SS has not been reported before. To investigate if this observation was due to chance, a new series of 16 patients with primary SS were HLA typed. In this new group, the frequencies of both Dw2 and Dw3 were significantly increased, while the frequency of Dw4 was significantly decreased. In the whole group of primary SS patients, the frequencies of Dw2 were 56.3% (relative risk = 3.7; p less than 0.001). Dw3:50.0% (relative risk = 2.8; p less than 0.01) and Dw4: 6.3% (relative risk = 0.28; p less than 0.05). We conclude that genetic factors associated with the HLA-system are involved in the development of Sjögren's syndrome and that these genetic factors are different in primary and secondary Sjögren's syndrome. In primary Sjögren's syndrome, the association with both Dw2 and Dw3 might suggest a further heterogeneity of the syndrome.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6941466     DOI: 10.3109/03009748109095284

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  14 in total

1.  Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies.

Authors:  Barbara M Segal; Abu N M Nazmul-Hossain; Ketan Patel; Pamela Hughes; Kathy L Moser; Nelson L Rhodus
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2011-04-16

2.  Chronic relapsing inflammatory polyneuropathy complicating sicca syndrome.

Authors:  M Gross
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-07       Impact factor: 10.154

3.  High-resolution HLA analysis of primary and secondary Sjögren's syndrome: a common immunogenetic background in Mexican patients.

Authors:  Gabriela Hernández-Molina; Gilberto Vargas-Alarcón; Jose M Rodríguez-Pérez; Nancy Martínez-Rodríguez; Guadalupe Lima; Jorge Sánchez-Guerrero
Journal:  Rheumatol Int       Date:  2014-09-28       Impact factor: 2.631

4.  Nervous system disease, immunological features, and HLA phenotype in Sjögren's syndrome.

Authors:  A Hietaharju; M Korpela; J Ilonen; H Frey
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

Review 5.  Genetics of Sjögren's syndrome.

Authors:  Leyla Y Teos; Ilias Alevizos
Journal:  Clin Immunol       Date:  2017-05-03       Impact factor: 3.969

6.  Antibodies to gliadin, gluten and reticulin glycoprotein in rheumatic diseases: elevated levels in Sjögren's syndrome.

Authors:  A M Teppo; C P Maury
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

Review 7.  Genes and Sjögren's syndrome.

Authors:  Beth L Cobb; Christopher J Lessard; John B Harley; Kathy L Moser
Journal:  Rheum Dis Clin North Am       Date:  2008-11       Impact factor: 2.670

8.  HLA antigens in Italian patients with primary Sjögren's syndrome.

Authors:  C Vitali; A Tavoni; G Rizzo; R Neri; A D'Ascanio; R Cristofani; S Bombardieri
Journal:  Ann Rheum Dis       Date:  1986-05       Impact factor: 19.103

Review 9.  Genetic aspects of Sjögren's syndrome.

Authors:  Anne I Bolstad; Roland Jonsson
Journal:  Arthritis Res       Date:  2002-09-24

Review 10.  Advances in the Aetiophatogenesis of Sjögren's Syndrome: a Literature Review.

Authors:  Pedro de Sousa Gomes; Gintaras Juodzbalys; Maria Helena Fernandes; Zygimantas Guobis
Journal:  J Oral Maxillofac Res       Date:  2012-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.